CAR-T cell therapy for ovarian cancer enters next phase of testing
A Phase 1 clinical trial evaluating escalating doses of Anixa Biosciences’ experimental CAR T-cell therapy for recurrent ovarian cancer has begun dosing participants…
Gynecological cancer
Trial of BAT8006 for form of ovarian cancer doses 1st patient
The first patient has been dosed in a Phase 3 trial testing the investigational therapy BAT8006 in people with platinum-resistant ovarian cancer, according to the…
Ovarian cancer immunotherapy found to boost immune response
IMNN-001, Imunon’s experimental immunotherapy for advanced ovarian cancer, boosts the body’s natural immune response by increasing levels of immune signaling proteins that aid in…
1st patient dosed in trial of Enhertu for HER2 endometrial cancer
A Phase 3 clinical trial of Enhertu, a therapy developed by Daiichi Sankyo and AstraZeneca, has begun dosing its first patient with…
Relacorilant delays ovarian cancer disease progression: Trial data
Relacorilant lowered the risk of disease progression and death by about 30% when used on top of standard chemotherapy in people with platinum-resistant ovarian cancer.
FDA fast tracks PHST001 as treatment for ovarian cancer
Pheast Therapeutics has received fast track designation from the U.S. Food and Drug Administration (FDA) for PHST001, its candidate treatment for ovarian cancer, a type…
Pembrolizumab improves survival outcomes in ovarian cancer trial
Treatment with pembrolizumab — an immune-modulating therapy sold for some cancers under the brand name Keytruda — improved survival among people with platinum-resistant ovarian cancer…
Testosterone in gender-affirming care doesn’t raise cancer risk
The use of testosterone as part of gender-affirming care does not increase the risk of gynecological cancers in transgender men or gender-diverse people, a study…
World Ovarian Cancer Day to be observed May 8
Thursday is World Ovarian Cancer Day, an annual effort to raise awareness about ovarian cancer, the second most common type of gynecological cancer.
Tepylute for breast, ovarian cancer launched in US
Tepylute (thiotepa), a chemotherapy medication from Shorla Oncology that was approved last year for treating certain breast and ovarian cancers, has launched in the…
